BME:GRFBiotechs
Assessing Grifols (BME:GRF) Valuation After H1 2025 Results And Dividend Reinstatement
Grifols (BME:GRF) has drawn fresh attention after its H1 2025 update, reporting €3.7b in revenue, higher adjusted EBITDA, reaffirmed full year guidance, a stronger free cash flow outlook and a reinstated interim dividend.
See our latest analysis for Grifols.
Despite the solid H1 2025 update, the share price has had a weak run, with a 30 day share price return of 5.72% and a 90 day share price return showing a 21.56% decline, while the 1 year total shareholder return of 15.18% reflects a...